Helmy Eltoukhy - 19 Nov 2021 Form 4 Insider Report for Guardant Health, Inc. (GH)

Signature
/s/ John Saia, as attorney-in-fact for Helmy Eltoukhy
Issuer symbol
GH
Transactions as of
19 Nov 2021
Transactions value $
$10,048,130
Form type
4
Filing time
23 Nov 2021, 18:07:37
Previous filing
17 Aug 2021
Next filing
16 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH COMMON STOCK Purchase $3.68M +37.6K +2.03% $97.90 1.89M 19 Nov 2021 Direct F1
transaction GH COMMON STOCK Purchase $1.23M +12.4K +0.66% $98.75 1.9M 19 Nov 2021 Direct F2
transaction GH COMMON STOCK Purchase $286K +3.11K +0.16% $92.23 1.9M 23 Nov 2021 Direct F3
transaction GH COMMON STOCK Purchase $2.46M +26.4K +1.39% $93.04 1.93M 23 Nov 2021 Direct F4
transaction GH COMMON STOCK Purchase $470K +5K +0.26% $94.00 1.94M 23 Nov 2021 Direct
transaction GH COMMON STOCK Purchase $478K +5K +0.26% $95.50 1.94M 23 Nov 2021 Direct
transaction GH COMMON STOCK Purchase $1.44M +14.9K +0.77% $96.83 1.96M 23 Nov 2021 Direct F5
transaction GH COMMON STOCK Purchase $9.8K +100 +0.01% $98.00 1.96M 23 Nov 2021 Direct
holding GH COMMON STOCK 366K 19 Nov 2021 Shares held by Eltoukhy Investments, L.P.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.445 to $98.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.71 to $98.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.88 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.88 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.